
Keywords: Botulinum toxins; Clinical trial; AE; Adverse event; BoNT; Botulinum neurotoxin; CD; Cervical dystonia; CGRP; calcitonin gene-related peptide; CP; cerebral palsy; IGA; Investigator's Global Assessment; IL-6; Interleukin 6; MMP-1; Matrix metalloproteinase-